Compare Davita Inc (DVA) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs First Citizens BancShares Inc — how do they compare? Davita Inc trades at $230.93 (market cap $14.92B), while First Citizens BancShares Inc trades at $2,065.81 (market cap $23.65B). The key difference: First Citizens BancShares Inc is the larger of the two by market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | FCNCA | |
|---|---|---|
Market Cap | $14.92B | $23.65B |
Sector | Health | Sector/Thematic |
52-Week High | $235.71 | $2.20K |
52-Week Low | $103.87 | $1.64K |
Enterprise Value | $27.47B | — |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
First Citizens BancShares (FCNCA) trades at $2,106.06, up 0.64% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $44.86 exceeding expectations by 13.4%. Recent developments include expansion of commercial banking capabilities and the planned retirement of the Silicon Valley Bank brand name in Q4 2026. The company maintains solid profitability with a 24.35% net income margin and 10.5% ROE, supported by $9.25B in revenue for 2025.
FCNCA presents a mixed investment case with strong fundamentals but cautious analyst sentiment. While valuation appears reasonable at 11.89 P/E and 1.18 P/B ratios, the majority of analysts (81.82%) maintain Hold ratings. Key opportunities include continued earnings momentum and strategic brand alignment, while risks involve margin pressure and credit exposure in the tech sector. The consensus price target of $2,320 suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
